A Bile Acid’s Unexpected Role in Protecting the Heart from Chemotherapy
A new study using Mendelian randomization, a genetic analysis technique, provides causal evidence that the hydrophilic bile acid glycoursodeoxycholic acid (GUDCA) may protect against cardiovascular adverse events linked to the chemotherapy drug carfilzomib. The research, published in Clinical Pharmacology & Therapeutics, validated an initial metabolomics finding in an independent patient cohort, showing higher GUDCA levels were associated with lower cardiotoxicity risk. The genetic analysis further supported a robust causal protective effect, with implicated biological pathways pointing to potassium channel regulation and thromboxane signaling.
Why it might matter to you: For emergency physicians managing acute cardiac events, understanding the biological mechanisms that modulate cardiovascular vulnerability is crucial. This research highlights a potential biomarker for risk stratification in patients presenting with cardiotoxicity, a common and serious complication of many cancer therapies. It underscores the growing importance of pharmacogenomics and metabolomics in predicting and managing drug-related emergencies in acute care settings.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
